Novozymes Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Ester Baiget
Chief executive officer
€6.8m
Total compensation
| CEO salary percentage | 21.69% |
| CEO tenure | 5.7yrs |
| CEO ownership | n/a |
| Management average tenure | 4.8yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | €565m |
| Mar 31 2025 | n/a | n/a | €459m |
| Dec 31 2024 | €7m | €1m | €306m |
| Sep 30 2024 | n/a | n/a | €279m |
| Jun 30 2024 | n/a | n/a | €283m |
| Mar 31 2024 | n/a | n/a | €334m |
| Dec 31 2023 | €4m | €1m | €406m |
| Sep 30 2023 | n/a | n/a | €430m |
| Jun 30 2023 | n/a | n/a | €460m |
| Mar 31 2023 | n/a | n/a | €487m |
| Dec 31 2022 | €3m | €1m | €494m |
| Sep 30 2022 | n/a | n/a | €460m |
| Jun 30 2022 | n/a | n/a | €418m |
| Mar 31 2022 | n/a | n/a | €416m |
| Dec 31 2021 | €3m | €1m | €423m |
| Sep 30 2021 | n/a | n/a | €427m |
| Jun 30 2021 | n/a | n/a | €409m |
| Mar 31 2021 | n/a | n/a | €389m |
| Dec 31 2020 | €3m | €927k | €380m |
Compensation vs Market: Ester's total compensation ($USD8.00M) is about average for companies of similar size in the Danish market ($USD6.28M).
Compensation vs Earnings: Ester's compensation has increased by more than 20% in the past year.
CEO
Ester Baiget (54 yo)
Ms. Ester Baiget serves as Chief Executive Officer and President of Novonesis A/S since joining on February 1, 2020. She serves as Member of Supervisory Board at Akzo Nobel N.V. since 2022. She served as t...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 5.7yrs | €6.81m | no data | |
| Executive VP & CFO | 1.9yrs | €2.92m | no data | |
| Chief Operating Officer | 1.8yrs | €1.03m | no data | |
| Chief Scientific Officer | 5.1yrs | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Vice President of Global Sales & Marketing | no data | no data | no data | |
| Executive Vice President of People & Stakeholder Relations | 4.5yrs | no data | no data | |
| Executive Vice President of Planetary Health Biosolutions | 9.7yrs | €1.02m | no data | |
| EVP of Human Health Biosolutions and Strategy & Integration | 1.8yrs | no data | no data | |
| Consultant | 9.7yrs | €1.17m | no data |
Experienced Management: NSIS B's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Employee Representative Director | less than a year | €66.91k | no data | |
| Independent Chairman | 5.7yrs | €329.30k | 0.0013% DKK 2.3m | |
| Independent Director | 8.7yrs | €159.10k | no data | |
| Non-Independent Director | 8.7yrs | €109.80k | 0.00022% DKK 400.6k | |
| Vice Chair of the Board | 5.7yrs | €176.60k | 0.0013% DKK 2.3m | |
| Independent Director | 1.6yrs | €90.50k | 0.00043% DKK 783.0k | |
| Independent Director | 1.6yrs | €120.70k | 0.00033% DKK 600.9k | |
| Employee Representative Director | 4.6yrs | €109.80k | 0.00014% DKK 254.9k | |
| Independent Director | 3.6yrs | €116.20k | 0.00021% DKK 382.4k | |
| Employee Representative Director | less than a year | no data | no data | |
| Employee Representative Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
Experienced Board: NSIS B's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 22:31 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novozymes A/S is covered by 41 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Vitfell-Rasmussen | ABG Sundal Collier |
| Carla Bänziger | Bank Vontobel AG |
| Sebastian Satz | Barclays |